CA3195597A1 - Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders - Google Patents

Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders

Info

Publication number
CA3195597A1
CA3195597A1 CA3195597A CA3195597A CA3195597A1 CA 3195597 A1 CA3195597 A1 CA 3195597A1 CA 3195597 A CA3195597 A CA 3195597A CA 3195597 A CA3195597 A CA 3195597A CA 3195597 A1 CA3195597 A1 CA 3195597A1
Authority
CA
Canada
Prior art keywords
compound
pharmaceutically acceptable
disease
solvate
metalloenzyme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3195597A
Other languages
English (en)
French (fr)
Inventor
Jonnie R. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Miralogx LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3195597A1 publication Critical patent/CA3195597A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3195597A 2020-10-16 2021-10-16 Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders Pending CA3195597A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063092594P 2020-10-16 2020-10-16
US63/092,594 2020-10-16
PCT/US2021/055327 WO2022082079A1 (en) 2020-10-16 2021-10-16 Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders

Publications (1)

Publication Number Publication Date
CA3195597A1 true CA3195597A1 (en) 2022-04-21

Family

ID=81209377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3195597A Pending CA3195597A1 (en) 2020-10-16 2021-10-16 Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders

Country Status (9)

Country Link
US (1) US20230295125A1 (ja)
EP (1) EP4228628A1 (ja)
JP (1) JP2023546295A (ja)
KR (1) KR20230088720A (ja)
CN (1) CN116528855A (ja)
AU (1) AU2021361997A1 (ja)
CA (1) CA3195597A1 (ja)
IL (1) IL302082A (ja)
WO (1) WO2022082079A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907315B (zh) * 2022-05-17 2023-09-12 重庆医科大学 Selitrectinib中间体的合成方法
WO2024050374A2 (en) * 2022-09-02 2024-03-07 Miralogx Llc Anti-inflammatory compounds, pharmaceutical compositions, and methods of treating hemochromatosis, and other disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) * 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo

Also Published As

Publication number Publication date
KR20230088720A (ko) 2023-06-20
IL302082A (en) 2023-06-01
JP2023546295A (ja) 2023-11-01
WO2022082079A1 (en) 2022-04-21
US20230295125A1 (en) 2023-09-21
AU2021361997A9 (en) 2024-02-08
AU2021361997A1 (en) 2023-06-15
CN116528855A (zh) 2023-08-01
EP4228628A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
US10588889B2 (en) Methods of treating hyperalgesia
CA3195597A1 (en) Metalloenzyme inhibitors for treating cancers, alzheimer's disease, hemochromatosis, and other disorders
US20080188524A1 (en) Methods of treating pain
US11161849B2 (en) Inhibiting the transient receptor potential al ion channel
EP3341380B1 (en) Brain-penetrant chromone oxime derivative for the therapy of levodopa-induced dyskinesia
JP2009530263A (ja) 代謝症候群および/または肥満および/または異常リポ蛋白血症を処置することを目的とした薬物を調製するためのcrf1レセプター・アンタゴニストの使用
EP2681209B1 (en) Compounds and methods for the treatment of pain and other disorders
US12116341B1 (en) Pharmaceutical compounds, pharmaceutical compositions, and methods of treating asthma and other disorders
US20130338116A1 (en) Compounds and methods for the treatment of pain and other diseases
US20240174650A1 (en) 8-(picolinamide) substituted coumarin compound, and preparation method therefor and use thereof
CN111432814B (zh) 用于减轻或治疗包括脆性X染色体综合征、Angelman综合征或Rett综合征的发育障碍的氨基甲酸酯化合物的用途
WO2004028526A1 (ja) ベンズアミド誘導体を有効成分とするリウマチ治療剤
JP4604147B2 (ja) クマリン誘導体
WO2023154412A1 (en) Anti-inflammatory compounds, pharmaceutical compositions, and treatment methods
US9745275B2 (en) Pain-related compound and medical composition
US10800733B2 (en) Acetophenone compound, preparation method therefor, and application thereof in blood lipid regulation
WO2010098298A1 (ja) 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物
CN111303161B (zh) 嘧啶并氮杂环类化合物及其用途
WO2023096854A1 (en) Acetylcholine receptor agonists and methods of treating neurological disorders and neuropathic pain
WO2024050374A2 (en) Anti-inflammatory compounds, pharmaceutical compositions, and methods of treating hemochromatosis, and other disorders
WO2023158702A1 (en) Anticancer compounds, pharmaceutical compositions, and methods of treating cancers